Sutro Biopharma, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)	1 Months Ended									12 Months Ended
	Nov. 30, 2023 USD ($) Installment	Oct. 31, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($) PerformanceObligation Program	Apr. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Jul. 31, 2018 USD ($) Program	Aug. 31, 2017 Program	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Apr. 30, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable, reserve for credit losses										$ 0	$ 0
Shares \| shares										167,780	167,780	167,780
Vaxcyte, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
First installment milestone payment received	$ 50,000,000
Additional milestone payment receivable	$ 25,000,000
Deferred revenue										$ 0	$ 17,500,000
Nonrefundable, non-creditable upfront payment receivable											10,000,000
Common stock fair value											$ 7,500,000
Payment received from definitive agreement		$ 5,000,000
Recognition of up front payment										97,500,000
Additional milestone payment										60,000,000
Shares \| shares											167,780
Number of installments \| Installment	2
Blackstone Life Sciences
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received			$ 140,000,000							140,000,000
2019 EMD Serono Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue										0	$ 0
BMS Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of programs advancing through preclinical development \| Program									4
Deferred revenue										0	0
2018 BMS Master Services Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue										0	3,100,000
2018 Merck Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue										$ 0	0
Milestone payment receivable upon initiation of IND enabling toxicology study													$ 15,000,000
2018 Merck Agreement \| Merck Sharp & Dohme Corp
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment received											10,000,000
Milestone payment received											2,500,000
Additional milestone payment received											7,500,000
Number of target programs \| Program								2
Initial transaction price								$ 60,000,000
Revenue recognition aggregate contingent payments eligible to receive												$ 500,000,000
Milestone method revenue recognition description										If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration
First Cytokine-Derivative Program \| Merck Sharp & Dohme Corp
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received							$ 5,000,000
Extended research term							1 year
2020 Merck Master Services Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue										$ 0	0
Supply Agreement \| Vaxcyte, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reimbursements expenses accruals										6,900,000	4,800,000
Reimbursements expenses										8,600,000	12,400,000	8,900,000
Tasly License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized from contingent payment										5,000,000
Income tax charge related to contingent payment										500,000
Contingent payment recognized as deferred revenue										5,000,000
Withholding tax on deferred revenue										$ 500,000
Maximum refund period on termination of study										30 days
Minimum term of royalties receivable based on annual net sales						10 years
Nonrefundable upfront payment receivable						$ 40,000,000						40,000,000
Maximum potential payments related to development regulatory commercialization contingent payments and milestones					$ 350,000,000	$ 345,000,000						$ 345,000,000
Reduction of research and development expenses recognized										$ 0	0
Initial licensing payment due					25,000,000
Initial licensing payment in escrow					$ 15,000,000
Upfront payment revenue recognized											25,000,000
Upfront payment withholding tax amount											2,500,000
Astellas License and Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue										69,000,000	86,100,000
Number of target programs \| Program				3
Upfront payment received										90,000,000
Transaction price				$ 90,000,000
Nonrefundable, non-creditable upfront payment receivable											$ 90,000,000
Number of performance obligations \| PerformanceObligation				4
Recognition of up front payment				$ 89,100,000
Estimated service period				4 years
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate										422,500,000
Upfront payment revenue not recognized										$ 32,800,000
Astellas License and Collaboration Agreement \| Future Services on Collaboration Joint Steering Committee ("JSC")
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognition of up front payment				$ 900,000
2015 License Member \| Blackstone Life Sciences \| Royalty
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received			$ 140,000,000
Revenue interest percentage			4.00%							4.00%